Zevra Therapeutics Inc (FRA:1GDA)
€ 4.22 -0.22 (-4.95%) Market Cap: 177.71 Mil Enterprise Value: 169.84 Mil PE Ratio: 0 PB Ratio: 3.99 GF Score: 50/100

Q3 2020 KemPharm Inc Earnings Call Transcript

Oct 29, 2020 / 08:30PM GMT
Release Date Price: €0.745
Operator

Good afternoon, ladies and gentlemen, and welcome to KemPharm's Q3 2020 Corporate Update Call. (Operator Instructions) As a reminder, this conference call may be recorded.

I would now like to turn the conference over to your host, Mr. Jason Rando, Tiberend Strategic Adviser. Sir, the floor is yours.

Jason Rando
Tiberend Strategic Advisors, Inc. - COO & EVP

Good afternoon, and thank you for joining our call today to discuss KemPharm's Third Quarter 2020 Financial and Corporate results.

Before we begin, I would like to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties and are subject to changes at any time, including, but not limited to, statements about KemPharm's expectations regarding future operating results. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations. Actual results may differ materially.

KemPharm disclaims any obligation to update or

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot